Compare · ARGX vs QNCX
ARGX vs QNCX
Side-by-side comparison of argenx SE (ARGX) and Quince Therapeutics Inc. (QNCX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and QNCX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $52.96B, about 3355.9x QNCX ($15.8M).
- Over the past year, ARGX is up 50.5% and QNCX is down 93.3% - ARGX leads by 143.8 points.
- QNCX has been more active in the news (9 items in the past 4 weeks vs 4 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 4 for QNCX).
- Company
- argenx SE
- Quince Therapeutics Inc.
- Price
- $853.73-5.62%
- $0.97+4.56%
- Market cap
- $52.96B
- $15.8M
- 1M return
- +4.55%
- -9.62%
- 1Y return
- +50.48%
- -93.28%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2019
- News (4w)
- 4
- 9
- Recent ratings
- 25
- 4
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- argenx to Host Autoimmune Myositis R&D Webinar
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
- SEC Form 6-K filed by argenx SE
Latest QNCX
- Cantor Fitzgerald initiated coverage on Quince Therapeutics with a new price target
- SEC Form 4 filed by Director Lamond David
- SEC Form 4 filed by Director Senner Christopher J.
- SEC Form 4 filed by Chief Corp. Affairs Officer Roberts Brigette
- SEC Form 3 filed by new insider Roberts Brigette
- SEC Form 8-K filed by Quince Therapeutics Inc.
- SEC Form D filed by Quince Therapeutics Inc.
- SEC Form D filed by Quince Therapeutics Inc.
- SEC Form SCHEDULE 13G filed by Quince Therapeutics Inc.
- SEC Form 8-K filed by Quince Therapeutics Inc.